| Autor: |
Perroud HA; Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario 2000, Argentina; National Scientific and Technical Research Council (CONICET), Rosario 2000, Argentina.; Italian Hospital of Rosario, Department of Clinical Oncology, Rosario 2000, Argentina., Scharovsky OG; Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario 2000, Argentina; National Scientific and Technical Research Council (CONICET), Rosario 2000, Argentina.; Research Council of the National University of Rosario (CIUNR), Rosario 2000, Argentina., Rozados VR; Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario 2000, Argentina., Alasino CM; Italian Hospital of Rosario, Department of Clinical Oncology, Rosario 2000, Argentina; Institute of Oncology of Rosario, Rosario 2000, Argentina. |
| Abstrakt: |
Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease. |
